Specialist healthcare investor Gilde Healthcare has agreed to carve out blood group and immune reagents business Sanquin Reagents from Sanquin Health Solutions.
The Dutch company provides materials for diagnostic research and drug development in the fields of hematology and immunology.
Sanquin is Gilde Healthcare’s debut deal from its €517m Fund IV, which it closed in March this year.
Firm partner Hugo de Bruin said, “We invest in companies that enable better healthcare at lower cost.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
“Sanquin Reagents’ strong R&D focus on developing new reagents fits with this investment philosophy.
“We see ample opportunity to expand the unique research and production capabilities and develop new reagents.”
GHPE IV was more than double the size of its predecessor Fund III, which Gilde Healthcare closed on €200m in 2019.
The vehicle is focuses on investments in profitable lower mid-market healthcare companies in North-west Europe with an EBITDA of €2m to €15m.
It is targeting healthcare subsectors including healthcare provision, service providers, and manufacturers of medical supplies and pharmaceutical companies.
Source: AltAssets
Can’t stop reading? Read more
Clearlake Capital strengthens executive bench as it scales global investment platform
Clearlake Capital strengthens executive bench as it scales global investment platform Clearlake...
Croatia’s Prosperus Growth acquires Neos to anchor IT platform strategy
Croatia’s Prosperus Growth acquires Neos to anchor IT platform strategy Croatian private equity...
Alter Capital takes control of Wifit Gyms to accelerate Iberian expansion
Alter Capital takes control of Wifit Gyms to accelerate Iberian expansion Alter Capital Desarrollo...